NKTR
NASDAQ · Pharmaceuticals
Nektar Therapeutics
$36.15
-2.33 (-6.06%)
Financial Highlights (FY 2026)
Revenue
113.29M
Net Income
-336,555,147
Gross Margin
100.0%
Profit Margin
-297.1%
Rev Growth
-15.7%
D/E Ratio
0.70
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 33.1% | 33.1% |
| Operating Margin | -253.7% | -228.3% | 30.6% | 35.1% |
| Profit Margin | -297.1% | -282.2% | 23.0% | 25.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 113.29M | 134.34M | 246.52M | 245.87M |
| Gross Profit | 113.29M | 134.34M | 81.64M | 81.42M |
| Operating Income | -287,377,588 | -306,699,667 | 75.50M | 86.21M |
| Net Income | -336,555,147 | -359,183,721 | 56.66M | 62.08M |
| Gross Margin | 100.0% | 100.0% | 33.1% | 33.1% |
| Operating Margin | -253.7% | -228.3% | 30.6% | 35.1% |
| Profit Margin | -297.1% | -282.2% | 23.0% | 25.3% |
| Rev Growth | -15.7% | -15.7% | +15.2% | +17.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 258.23M | 258.23M | 257.51M | 280.38M |
| Total Equity | 367.27M | 367.27M | 292.45M | 319.03M |
| D/E Ratio | 0.70 | 0.70 | 0.88 | 0.88 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -285,272,827 | -321,367,467 | 106.98M | 112.84M |
| Free Cash Flow | — | — | 45.61M | 47.98M |